Abstract:The depsipeptide FR900359 has been first described in literature in 1988 (Fujioka et al , 1988) to be isolated from a methanol extract of the whole plant of Ardisia crenata . FR900359 can be isolated from the leaves of A. crenata , but the very low quantities and the complex matrix prevent access to sufficient amounts of FR900359 to enable drug development efforts and potential commercial manufacturing. Almost two decades later, it has been discovered that FR900359 is in fact produced by a strictly obligate bacterial endosymbiont, Candidatus Burkholderia crenata , of the plant Ardisia crenata (Carlier et al , 2016). This study identified also the DNA sequence of the biosynthetic gene cluster (BGC) of FR900359. In order to identify alternative and scalable methods for production of FR900359, a genome mining effort on bacterial genomes from both public sequence databases and genome sequences generated from internal efforts at Novartis was initiated. Translated amino acid sequences of the FR900359‐BGC from Candidatus B. crenata were used as query sequence. While the query of public sequence databases did not return highly similar sequences, a gene cluster with very high homology in translated amino acid sequence and identical prediction of protein functions was discovered in the genome of Chromobacterium vaccinii DSM 25150, which had been sequenced internally at Novartis. Here we describe the genetic engineering of Chromobacterium vaccinii DSM 25150 resulting in mutants that exhibit improved production of FR900359 and improved characteristics concerning downstream processing and purification.

Condensation domain editing of the FR900359 assembly line yields a novel analog amenable to late-stage functionalization

Genetic Engineering of Chromobacterium Vaccinii DSM 25150 for Improved Production of FR900359

Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics

Engineering site-selective incorporation of fluorine into natural product analogs

In Vitro Module Editing Of NRPS Enables Production Of Highly Potent Gq‐Signaling Inhibitor FR900359 Derived From Unculturable Plant Symbiont

High-throughput reprogramming of an NRPS condensation domain

Modification and de novo design of non-ribosomal peptide synthetases using specific assembly points within condensation domains

A straightforward access to trifluoromethylated natural products through late-stage functionalization

Deciphering the Late Biosynthetic Steps of Antimalarial Compound FR-900098

A Promiscuous Halogenase for the Derivatization of Flavonoids

α,β-Desaturation and Formal β-C(sp3)-H Fluorination of N-Substituted Amines: A Late-Stage Functionalization Strategy Enabled by Electrochemistry

Chemoenzymatic synthesis of fluorinated polyketides

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Functionalization of Chlorotonils: Dehalogenil as Promising Lead Compound for In Vivo Application

Algorithm-aided engineering of aliphatic halogenase WelO5* for the asymmetric late-stage functionalization of soraphens

Semirational Design of Fluoroacetate Dehalogenase RPA1163 for Kinetic Resolution of α-Fluorocarboxylic Acids on a Gram Scale

Synthesis of Cytochalasan Analogues with Aryl Substituents at Position 10

Asymmetric Dirhodium-Catalyzed Modification of Immunomodulatory Imide Drugs and Their Biological Assessment

Sustainable And Scalable Enzymatic Production, Structural Elucidation, And Biological Evaluation Of Novel Phlorizin Analogues

Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-fargesone A As a Novel FXR Agonist

Selective synthesis of an elusive C-functionalized bis-cyclam through the bis-aminal route and study of its inhibition properties of CXCR4 chemokine receptor